Trial Profile
A double-blind, randomized, placebo-controlled study of the efficacy, safety/tolerability, and pharmacokinetic profile of UCB0942 in adult patients with highly drug-resistant focal epilepsy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Jul 2022
Price :
$35
*
At a glance
- Drugs Padsevonil (Primary)
- Indications Partial epilepsies
- Focus Proof of concept; Therapeutic Use
- Sponsors UCB
- 11 May 2018 According to UCB Media release, data from this trial will be presented at EILAT Conference.
- 05 Dec 2017 Primary endpoint has not been met. (75 % responder rate (75 % RR, proportion of subjects who achieve 75 % reduction in focal seizure frequency))
- 05 Dec 2017 Results presented at the 71st Annual Meeting of the American Epilepsy Society